No coin nor oath required. For personal study only.
WASHINGTON, DC . . . Two ongoing studies showed adults with type 1 or type 2 diabetes treated with Exubera (insulin human [rDNA origin]) inhalation powder experienced sustained blood sugar control over a two-year period and gained about half as much weight as those taking injected insulin. These Phase III data were presented at the Annual Scientific Sessions of the American Diabetes Association in June.
Exubera, marketed by Pfizer and a product of a developmental collaboration between Pfizer and Nektar Therapeutics, is the first inhaled form of insulin and the first insulin option in the U.S., European Union, and Brazil in more than 80 years that does not need to be administered by injection.
In the U.S., Exubera is approved for the treatment of adults with type 1 or type 2 diabetes for the control of high blood sugar levels. In patients with type 2 diabetes, Exubera can be used alone or in combination with diabetes pills or longer-acting insulin. In patients with type 1 diabetes, Exubera should be used in combination with a longeracting insulin.
U.S. introduction of Exubera began in mid-July. It is also currently available in Germany and Ireland, and is expected to be available in the United Kingdom soon.
''These findings are important because they confirm that people who switched from rapid-acting injectable insulin to Exubera experienced no loss of blood sugar control,'' says Julio Rosenstock, lead investigator from the Dallas Diabetes and Endocrine Center at Medical City and also a clinical professor of medicine at the
๐ SIMILAR VOLUMES